Videos

Experts discuss examples of financial challenges patients experience that impact medication adherence, and potential solutions to address these challenges.

Pharmacy Times interviewed Craig Freyer, PharmD, BCOP, and Andrew Lin, PharmD, BCOP, to discuss their presentation at the recent ATOPP 2021 summit on re-examining the why, who, and where of CAR T therapy.

Pamela Spicer, senior analyst at Datamonitor with Informa Pharma Intelligence, said there are no other currently available treatments for Alzheimer disease that get to the root of the condition.

Pamela Spicer, senior analyst with Datamonitor Healthcare, said aducanumab is a once-monthly infusion with a 6-month titration schedule.

Dennis O’Neill, president and board member of BIOMEDICAN, discusses the current field of research assessing biosynthesis therapeutics that use psychedelics and rare cannabinoids.

An overview of CGRP antagonists approved as preventive therapy for migraine and recommendations for appropriate dosing and administration to patients.

Factors that need to be considered when determining patient candidacy for over-the-counter herbal products and nutritional supplements available as preventive therapy for migraine and recommendations for educating patients about their use.

In an interview with Pharmacy Times®and Directions in Oncology Pharmacy®, Chad Hatfield, PharmD, MHA, BCPS, chief pharmacy officer at UC Davis Medical Center, discussed how data analytics are used in oncology pharmacy practice.

Brexucabtagene autoleucel (Tecartus, Kite Pharma) is a cell-based gene therapy for the treatment of adult patients with mantle cell lymphoma who have not responded to or who have relapsed following other treatments.

Pharmacy Times spoke with Bhavesh Shah, associate chief pharmacy officer for hematology/oncology, about his session titled Stand Strong Against Platelet Destruction With Tavalisse®: A Patient’s ITP Treatment Journey, which he presented at the 2021 ATOPP Summit.

A panel of experts share their final thoughts on the role of prophylaxis in hemophilia A and the importance of shared decision making and education.

Key opinion leaders discuss how specialty pharmacies can work collaboratively to overcome both financial and nonfinancial barriers in hemophilia A.

Anastasia Abramson, PharmD, MBA, outlines administration costs associated with prophylactic treatments for hemophilia A as well as other financial barriers from a specialty pharmacy perspective.

In an interview with Pharmacy Times, Chris Zaleski, PharmD, RPh, said pharmacy technicians are essential pharmacy team members to prevent dispensing errors and enhance patient care.

Mary Reed, DrPH, research scientist at Kaiser Permanente, discussed the challenges encountered by health systems and patients during the shift to online care.

Pharmacy Times spoke with Bhavesh Shah, associate chief pharmacy officer for hematology/oncology, about his session titled Stand Strong Against Platelet Destruction With Tavalisse®: A Patient’s ITP Treatment Journey, which he presented at the 2021 ATOPP Summit.

Margetuximab-cmkb (Margenza) was approved in December 2020 in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have previously received 2 or more anti-HER2 regimens, at least one of which for metastatic disease.

Pharmacy Times spoke with Bhavesh Shah, associate chief pharmacy officer for hematology/oncology, about his session titled Stand Strong Against Platelet Destruction With Tavalisse®: A Patient’s ITP Treatment Journey, which he presented at the 2021 ATOPP Summit.

Experts discuss triggers for initiating therapy in a patient with CLL, in addition to the goals of therapy.

Taylor M. Weis, PharmD, BCOP, discusses NCCN guidelines for first-line therapy as well as the rationale behind the rapid change in treatment concepts for CLL.

Experts in cardiology and pharmacy provide an overview of the cardiac benefit of SGLT2 inhibitors by discussing their mechanism of action, safety, efficacy, and cost burden for patients with heart failure.

Key opinion leaders in cardiology and pharmacy consider the role of ivabradine to reduce heart rate and lower the risk of hospitalization for patients with heart failure.

Suzanne Soliman, PharmD, BCMAS, shares startling data and explains how the need to optimize patient care led to the development of Prescription Discount Programs.

Lisa King, RPh, provides an overview of Prescription Discount Programs including purpose, how it works, differences from other assistance programs, and benefits.

Mary Reed, DrPH, research scientist at Kaiser Permanente, discussed the changes made to health care practices in light of the COVID-19 pandemic that she would like to see remain in place in the future.

Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, discussed the importance of the FDA’s expedited approval process for infigratinib in the treatment of previously treated locally advanced or metastatic cholangiocarcinoma.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the implications of the DARE-19 trial results assessing dapagliflozin as a treatment for patients with type 2 diabetes hospitalized with COVID-19.

Although pharmaceutical companies have already begun developing COVID-19 vaccine boosters, Michael Haydock of Informa Pharma Intelligence said boosters may not be necessary in the fall of 2021.

In an interview with Pharmacy Times® and Directions in Oncology Pharmacy®, Abizer Gaslightwala, vice president and head of the U.S. Hematology and Oncology division at Jazz Pharmaceuticals discusses the company’s new digital resource, Nothing Small About It.

Mary Reed, DrPH, research scientist at Kaiser Permanente, discussed how COVID-19 forced health systems to shift primarily to telehealth, and the impact this had on patients with diabetes.